Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
| dc.contributor | Compiled by the New Jersey State Library | en_US |
| dc.date.accessioned | 2019-08-01T13:27:48Z | |
| dc.date.available | 2019-08-01T13:27:48Z | |
| dc.description.abstract | Year: 2016; Chapter: 73 | |
| dc.identifier.uri | http://hdl.handle.net/10929.1/26498 | |
| dc.title | Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements. | |
| dc.type | Legislative History | en_US |
| lg.NJSA | 24:6B-1 & 24:6B-2 | en_US |
| lg.billNumber | S2024 | en_US |
| lg.chapter | 073 | en_US |
| lg.njlhid | L2016c73 | en_US |
| lg.synopsis | Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements. | |
| lg.title | Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements. | |
| lg.yearEnacted | 2016 | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- L2016c73.pdf
- Size:
- 1.66 MB
- Format:
- Adobe Portable Document Format
- Description:
- L2016c73